Late-Onset Hypogonadism (LOH)
EMAS Diagnostic Criteria, Prevalence, and the Physiology of the Aging HPG Axis
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No FDA-approved indication for age-related decline alone; testosterone is approved only for hypogonadism due to an underlying medical condition (2015 labeling action)
Reference only. Not medical advice.
What can go wrong
The clinical risk is mislabeling: applying a 'LOH' diagnosis to men whose symptoms stem from sleep apnea, depression, obesity, alcohol, opioids, or simply normal aging, then committing them to lifelong testosterone therapy with its suppression of fertility and downstream monitoring burden. Conversely, genuine secondary hypogonadism (low T with inappropriately low LH/FSH) can signal pituitary disease and warrants workup, not a same-day prescription.
This is something to take to a clinician. The Atlas can tell you what is known about late-onset hypogonadism (loh) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Late-onset hypogonadism (LOH) is the syndrome of biochemically confirmed low testosterone PLUS specific symptoms in aging men. The pivotal evidence comes from the European Male Ageing Study (EMAS; Wu et al., NEJM 2010), which screened 3,369 men aged 40-79 and derived a syndromic definition requiring at least three sexual symptoms (poor morning erection, low libido, and erectile dysfunction) together with total testosterone below 11 nmol/L (~317 ng/dL) and free testosterone below 220 pmol/L. Under those criteria, true LOH prevalence was only 2.1% overall, rising with age. The gap between that figure and the marketing claim that low T is epidemic is the central tension of this entire library.
A real but uncommon and strictly defined syndrome, far rarer than the marketplace implies.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
With age, the hypothalamic-pituitary-gonadal axis changes on multiple levels: Leydig cell number and testosterone output decline modestly, sex-hormone-binding globulin (SHBG) rises (lowering the free fraction faster than total T falls), and the hypothalamic GnRH pulse generator becomes less responsive. The result is a slow drift toward lower bioavailable testosterone. EMAS demonstrated that only the three SEXUAL symptoms tracked tightly with the testosterone level; physical and psychological symptoms (fatigue, low mood, reduced vigor) correlated weakly and are heavily confounded by comorbidity, depression, obesity, and poor sleep.
Why the symptom list is the trap
EMAS started with nine candidate symptoms and found that fatigue, sadness, and reduced physical performance were essentially as common in men with normal testosterone as in those with low testosterone. The marketplace inverts this: telehealth 'low T quizzes' lead with exactly those nonspecific symptoms, which capture most middle-aged men regardless of their actual androgen status. Wu's data argue that a man with low energy and normal libido is unlikely to have hormonally meaningful hypogonadism.
What it does to fertility
LOH itself does not abolish fertility, but treating it with exogenous testosterone suppresses LH/FSH and spermatogenesis, frequently causing reversible (sometimes persistent) infertility. Men wishing to preserve fertility require alternatives such as clomiphene/enclomiphene or hCG.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Two early-morning fasting total testosterone measurements
- LH and FSH to distinguish primary vs secondary
- SHBG (and calculated free T) where total T is borderline
- Prolactin and pituitary workup if secondary hypogonadism
- Hematocrit and PSA at baseline if treatment considered
What people get wrong
Often saidHalf of middle-aged men have low T
ActuallySymptomatically confirmed late-onset hypogonadism affected only ~2.1% of men in EMAS. The much higher figures quoted in marketing count any single low lab value, often a non-fasting afternoon draw, without required symptoms or confirmation.
Often saidLow energy and low mood mean low testosterone
ActuallyEMAS found these symptoms barely discriminate between men with normal and low testosterone. Only the three sexual symptoms tracked the hormone.
Who profits, and who pushes back
Frederick Wu
Emphasizes that only the three sexual symptoms tracked tightly with testosterone and that strict syndromic criteria yield low true prevalence, undercutting epidemic framing.
Bradley Anawalt
Argues that a single cutoff oversimplifies a continuous variable confounded by obesity, illness and SHBG, and that diagnosis requires confirmed low draws plus genuine symptoms.
Abraham Morgentaler
Contends that rigidly low thresholds underdiagnose symptomatic men who benefit from treatment, and that symptom burden should weigh alongside the absolute number.
Set against the alternatives
The competing definitions disagree mainly on where to set the total-testosterone line and how strict to make the symptom requirement. EMAS is the most conservative and syndromic, demanding three specific sexual symptoms plus both low total and free testosterone, which is why it yields just 2.1% prevalence. The Endocrine Society anchors to a CDC-harmonized 264 ng/dL lower limit, the AUA to 300 ng/dL confirmed on two morning draws, and ISSAM/EAU/ISSM to a higher 350 ng/dL threshold for consideration. The practical effect is that the same man can be 'normal' or 'hypogonadal' depending on which guideline and assay are applied, and the gap between strict syndromic prevalence and broad marketing claims is the central tension this entry documents.
| Definition | Total T cutoff | Symptom requirement | Note |
|---|---|---|---|
| EMAS (Wu 2010) | <11 nmol/L (~317 ng/dL) | 3 sexual symptoms + free T <220 pmol/L | Syndromic; 2.1% prevalence |
| Endocrine Society | <264 ng/dL (9.2 nmol/L) | Symptoms/signs + 2 low draws | CDC-harmonized range |
| AUA | <300 ng/dL | Symptoms/signs required | Two early-morning measurements |
| ISSAM / EAU / ISSM | <350 ng/dL (12 nmol/L) | Symptoms required | Higher threshold for consideration |
What we do not know
- Does treating symptomatic LOH change hard outcomes (mortality, function) versus treating the underlying comorbidity?
- Is the rising SHBG of aging a cause of symptoms or a marker of declining health?
- How much of measured 'decline' is aging per se versus accumulated illness (see the healthy-aging reanalyses)?
What could change
Free-testosterone standardizationBetter assays and reference ranges for the bioavailable fractionSymptom-weighted diagnosisModels combining symptom burden with biochemical thresholdsObesity and SHBG adjustmentRefining cutoffs for confounders that distort total testosteroneLongitudinal HPG-axis cohortsTracking who with biochemical low-T actually develops syndromic LOH
At a glance
- Defining study
- EMAS (Wu et al., NEJM 2010)
- Cohort
- 3,369 men, ages 40-79, 8 European centers
- Required symptoms
- 3 sexual symptoms (a priori)
- Total T threshold
- <11 nmol/L (~317 ng/dL)
- Free T threshold
- <220 pmol/L
- Overall prevalence
- 2.1%
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Late-Onset Hypogonadism (LOH). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
EMAS, Identification of Late-Onset Hypogonadism (Wu et al., NEJM)2010
Derived the 3-sexual-symptom + low-T syndromic definition; overall prevalence only 2.1%, rising from 0.1% (age 40-49) to 5.1% (age 70-79)
EMAS symptom analysis (Wu et al., JCEM)2008
Sexual symptoms, not physical/psychological symptoms, showed the strongest, dose-dependent relationship to declining testosterone
Endocrine Society Clinical Practice Guideline (Bhasin et al.)2018
Recommends diagnosing hypogonadism only with consistent symptoms AND unequivocally low morning T on two occasions, explicitly cautioning against treating age alone